Viking Therapeutics (NASDAQ: VKTX) has been a company to watch over the past few years. That's because the biotech is involved in one of the healthcare market's biggest growth areas: weight loss drugs. Viking hasn't yet commercialized a product, but it's nearing the finish line. The company's lead candidate is involved in two phase 3 trials, and it recently launched trials for an additional candidate. Viking aims to compete in a space dominated today by pharma giants Eli Lilly and Novo Nordisk. While I wouldn't expect Viking to oust these players from leadership, the company still could score a major win in the space. This is because demand is high, leaving room for more than one or two companies to operate here. And today, investors are looking at a key opportunity. Viking is trading about 23% below its $35 secondary offering price. Let's find out why this could be a gift for patient investors.
CryptoAlerta — análise de criptomoedas e mercado em tempo real